{
  "pmcid": "12416890",
  "sha256": "33565c8ff7a22454e81949f90665f99d85e9b78994409ae1cfff0e32cf177203",
  "timestamp_utc": "2025-11-09T23:37:03.597921+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.431450871080141,
    "reading_ease": 40.721475958188165,
    "word_count": 287
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Cardiopulmonary Bypass Flow Rates on Renal Function"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "parallel-arm randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Thirty-six adult patients undergoing cardiac surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either high flow (2.9 l · min–1 · m–2, n = 19) or standard flow (2.4 l · min–1 · m–2, n = 17)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine if a higher-than-standard CPB flow improves renal blood flow, oxygen demand–supply relationship, and function, and reduces tubular injury."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was renal blood flow, measured by para-aminohippuric acid clearance, over 60 minutes."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was stratified by eGFR and left ventricular ejection fraction using an online tool."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Neither patients nor clinicians were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Thirty-six adult patients undergoing cardiac surgery were randomised"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "High flow led to a larger increase in systemic oxygen delivery (100 [95% CI, 60 to 141] vs. 31 [1.9 to 65] ml · min–1 · m–2; P < 0.001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No perfusion-related adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov NCT272790."
      },
      "Funding": {
        "score": 1,
        "evidence": "Supported by Swedish State, ALF-agreement, Swedish Heart and Lung Foundation, and Gothenburg Society of Medicine."
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}